Clinical trials: Neuromyelitis Optica Spectrum Disorders
NMO Spectrum Disorder, MRI
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases.
- Conditions
- NMO Spectrum Disorder, MRI, Multiple Sclerosis, MOGAD
- Trial name
- NCT04106830
- Testing
- Intravenous steroid
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
AQP4+ NMOSD
A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
The goal of this clinical trial is to find out if the investigational medicine BMS-986353 is safe and well tolerated in adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT07573332
- Testing
- CC-97540 (BMS-986353), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center
Neuromyelitis Optica Spectrum Disorders
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
This is a single-center, randomized, open-label, placebo-controlled, dose-escalation trial. The objective of this research is to evaluate the safety, tolerability, and efficacy of intrathecal administration of human-induced…
- Trial name
- NCT06620809
- Testing
- Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Tongji Hospital
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive…
- Conditions
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis
- Trial name
- CRSP-AID-502 (NCT07804004)
- Testing
- CTX112
- Volunteers
- 220 people
- Sponsor
- CRISPR Therapeutics
AIRE Deficiency
Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies
Studying genetic predisposition in autoimmune neurological diseases could help improve diagnostic accuracy and offer new treatment possibilities
- Trial name
- NAD-AIRE (NCT06941584)
- Testing
- Test for AQP4, AChR, LGI1, and CASPR2 autoantibodies using cell-based assay, AIRE single gene sequencing, Molecular typing of HLA class I and II alleles
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neuromyelitis Optica Spectrum Disease (NMOSD), Ripertamab
Study on Efficacy Evaluation of Ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders
This clinical trial aims to evaluate the safety and efficacy of ripertamab in patients with neuromyelitis optica spectrum disorders (NMOSD). The key research objectives are as follows: 1.
- Trial name
- RIPERT-NMOSD (NCT07685678)
- Testing
- Ripertamab
- Volunteers
- 20 people
- Sponsor
- Zhongming Qiu
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
The French Multiple Sclerosis Registry
OFSEP is an observational cohort of Multiple Sclerosis (MS) and related disorders set up in France. It aims to provide a major epidemiological tool on MS for the scientific community in France and abroad.
- Trial name
- OFSEP (NCT02889965)
- Where
- France
- Volunteers
- 54,000 people
- Sponsor
- Hospices Civils de Lyon
Neuromyelitis Optica
Safety of Therapeutic Step-down in Neuromyelitis Optica
Neuromyelitis Optica (NMO) is a neuroinflammatory disease related to multiple sclerosis (MS). It affects young subjects and causes a lot of handicap without treatment.
- Trial name
- NMO (NCT05155644)
- Where
- France
- Volunteers
- 947 people
- Sponsor
- University Hospital, Strasbourg, France
Neuromyelitis Optica, NMO Spectrum Disorder
Pediatric NMOSD Observational Study
This study is being done to develop a database of pediatric patients in order to study the cause, early detection and best treatment for neuromyelitis optica spectrum disorder (NMOSD) in pediatric patients.
- Trial name
- NCT03766347
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack
Diagnosis of ON With or Without MS or NMOSD
This is both a prospective and retrospective study of patients with a known diagnosis of optic neuritis (ON) only, multiple sclerosis (MS) with ON, or neuromyelitis spectrum disorder (NMOSD) with ON.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Neuromyelitis Optica Spectrum Disorder Relapse, Neuromyelitis Optica Spectrum Disorder Progression
- Trial name
- NCT04131764
- Testing
- Reflex (Brightlamp Inc., Purdue University)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Jagannadha R Avasarala
Neuromyelitis Optica, Efgartigimod
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
This study aims to retrospective investigate the safety and effectiveness of Efgartigimod in the acute phase of neuromyelitis optica spectrum disorders (NMOSD) patients.
- Trial name
- NCT06118398
- Testing
- Intravenous methylprednisolone (IVMP) and Efgartigimod, IVMP
- Volunteers
- 24 people
- Sponsor
- Feng Jinzhou
Demyelinating Diseases, Multiple Sclerosis
Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve
The goal of this observational study is to longitudinally investigating subjects with inaugural acute optic neuritis (ON). The main questions it aims to answer are: Does the time to corticosteroid treatment affect the visual…
- Conditions
- Demyelinating Diseases, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Trial name
- ACON (NCT05605951)
- Testing
- non-interventional study
- Where
- 26 sites in United States, Argentina and 15 more
- Volunteers
- 200 people
- Sponsor
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul
Devic's Syndrome, Devic's Neuromyelitis Optica
Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders
Neuromyelitis optica (NMO) is a demyelinating and degenerative disorder of the central nervous system affecting vision and brain and spinal cord function which leads to accumulating disability with a 5 year-mortality of…
- Conditions
- Devic's Syndrome, Devic's Neuromyelitis Optica, Devic Syndrome, Devic's Disease
- Trial name
- NCT02249676
- Testing
- Autologous mesenchymal stem cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Medical University General Hospital
Multiple Sclerosis, Neuromyelitis Optica
MS and NMOSD in African-Americans
This is a prospective study that aims to collect and review neuromyelitis optica spectrum disorder (NMOSD) data from African American patients with a known diagnosis of multiple sclerosis (MS).
- Trial name
- NCT04131673
- Where
- United States
- Sponsor
- Jagannadha R Avasarala
Multiple Sclerosis, MS, Neuromyelitis Optica Spectrum Disorders
Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
The goal of this observational study is to learn about pathogenesis and clinical prognosis of CNS IIDD in the Chinese population and to provide evidence-based clues for clinical treatment decisions.
- Conditions
- Multiple Sclerosis, MS, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Acute Disseminated Encephalomyelitis
- Trial name
- NCT06541626
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Multiple Sclerosis, Transverse Myelitis
Biobank For MS And Other Demyelinating Diseases
To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated…
- Conditions
- Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis
- Trial name
- NCT00445367
- Where
- 10 sites in United States
- Volunteers
- 3,226 people, healthy volunteers welcome
- Sponsor
- Accelerated Cure Project for Multiple Sclerosis
NMO Spectrum Disorder
Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is an open-label, single-arm, single-center prospective pilot study to assess the efficacy and safety of transcranial temperol interference stimulation in patients with neuromyelitis optica spectrum disorder (NMOSD)…
- Trial name
- NCT07377305
- Testing
- 10Hz tTIS (2-4mA) Intervention
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Tang-Du Hospital
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previous treatment with rituximab…
- Trial name
- SAkuraBonsai (NCT05269667)
- Testing
- Satralizumab 120 mg
- Where
- 3 sites in United States, South Korea and 1 more
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
NMO Spectrum Disorder
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel.
- Trial name
- NCT05154734
- Testing
- Belimumab
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University General Hospital
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD)
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, Stiff Person Syndrome
- Trial name
- NCT07341828
- Testing
- CD20/BCMA-directed CAR-T cells
- Volunteers
- 15 people
- Sponsor
- Huashan Hospital